Each October, the pharmacy profession pauses to recognize technicians' decades-long evolution, from on-the-job trainees to nationally certified health care professionals.
|Videos|September 2, 2015
Behavioral Patterns that Contribute to a Patient's Propensity to Be More or Less Adherent
Bruce Berger, PhD, president of Berger Consulting LLC, discusses the behavioral patterns that contribute to a patient's propensity to be more or less adherent to their medications.
Advertisement
Bruce Berger, PhD, president of Berger Consulting LLC, discusses the behavioral patterns that contribute to a patient’s propensity to be more or less adherent to their medications.
This video was recorded at the 2015 NACDS Total Store Expo.
Advertisement
Related to this article
Experts on Lp(a) testing, statin myths, cognitive safety, and the 2025-2030 Dietary Guidelines share counseling points from the National Lipid Association's Fall Clinical Lipid Update meeting.
At-home chemotherapy for HR+ breast cancer works best when pharmacists guide oral regimens, boosting adherence, safety, and affordable access.
Managing medication safety in specialized populations requires a shift from standardized dosing to precise, patient-specific customization.
Emergency and ICU pharmacists would be most likely to see pneumonic plague. An expert reviews first-line agents, alternatives, and postexposure prophylaxis.
A former residency program director unpacks why this debate keeps resurfacing, and why some reasons people give for skipping residency may not hold up the way they think they do.
Eric Lawitz, MD, explains how pharmacists can discuss liver risk with patients with obesity and why a FIB-4 score from routine blood work is a good first step.
Pharmacogenomic-guided prescribing uses genetic data to protect patients from dangerous toxicities and get them the right drug at the right dose from the start.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Preparing Pharmacists for Psychedelic Medicine
2
Pneumonic Plague: What Pharmacists Need to Know About Treatment
3
Beyond Skin Clearance: What Litifilimab Could Mean for Cutaneous Lupus Care
4
FDA Approves First Once-Monthly Subcutaneous Olanzapine LAI for Adults With Schizophrenia
5